Marta. Chesi, et.al., AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies., Cancer cell, 2008, 13

http://rdf.ncbi.nlm.nih.gov/pubmed/18242516

Marta. Chesi, et.al., AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies., Cancer cell, 2008, 13

pubmed

allele

http://purl.org/net/cito/citesAsAuthority

• Tg(Igkv3-5*-MYC)#Plbe
  http://metadb.riken.jp/db/mgi_rdf/MGI:5441311

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• increased myeloma incidence_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0009440IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• increased plasmacytoma incidence_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0010286IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• decreased bone trabecula number_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0010869IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• abnormal bone structure_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0003795IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• premature death_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0002083IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• abnormal vertebrae morphology_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0000137IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• abnormal plasma cell differentiation_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0008099IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• abnormal plasma cell differentiation_Tg(BCL2)25Wehi/0
  http://metadb.riken.jp/0008099IC57BL6JWehiSJLJWehiTgBCL225Wehi0TgBCL225Wehi
• osteoporosis_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0000066IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• abnormal hemoglobin_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0001588IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• increased B cell derived lymphoma incidence_Tg(Igkv3-5-MYC)#Plbe/0
  http://metadb.riken.jp/0002023IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• increased IgG3 level_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0008502IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• abnormal immunoglobulin level_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0002490IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• anemia_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0001577IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• increased sensitivity to induced morbidity/mortality_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0009763IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• hindlimb paralysis_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0000755IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• increased plasmacytoma incidence_Tg(BCL2)25Wehi/0,Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0010286IC57BL6C57BL6JWehiSJLJWehiTgBCL225Wehi0TgIgkv35MYCPlbe0TgIgkv35MYCPlbeTgBCL225Wehi
• increased IgG1 level_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0008499IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• premature death_Tg(BCL2)25Wehi/0,Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0002083IC57BL6C57BL6JWehiSJLJWehiTgBCL225Wehi0TgIgkv35MYCPlbe0TgIgkv35MYCPlbeTgBCL225Wehi
• abnormal humoral immune response_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0001800IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• ascites_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0005324IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• increased plasma cell number_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0008097IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• decreased bone mineral density_Tg(Igkv3-5*-MYC)#Plbe/0
  http://metadb.riken.jp/0000063IC57BL6TgIgkv35MYCPlbe0TgIgkv35MYCPlbe
• abnormal B cell differentiation_Tg(BCL2)25Wehi/0
  http://metadb.riken.jp/0002144IC57BL6JWehiSJLJWehiTgBCL225Wehi0TgBCL225Wehi

class

http://purl.org/net/cito/citesAsAuthority

• Tg(Igkv3-5*-MYC)#Plbe
  http://metadb.riken.jp/db/mgi_rdf/MGI:5441311